PRTA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

666.67K

-68.6%

-0.559

-48.28%

0.00

-100%

-0.330

-70.54%

76.68M

+1634.73%

1.037

-144.3%

Estimates Revision

The market is revising Downward the revenue expectations for Prothena Corporation plc (PRTA) for FY2025, with the revenue forecasts being adjusted by -50.17% over the past three months. During the same period, the stock price has changed by 25.25%.

Revenue Estimates for FY2025

Revise Downward

-50.17%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.21%

In Past 3 Month

Stock Price

Go Up

+25.25%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast PRTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRTA is 21.20 USD with a low forecast of 11.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 10.220

Low

11.00

Averages

21.20

High

36.00

Current: 10.220

Low

11.00

Averages

21.20

High

36.00

BofA

Tazeen Ahmad

Underperform

maintain

$4 -> $8

2025-11-24

Reason

BofA

Tazeen Ahmad

Price Target

$4 -> $8

2025-11-24

maintain

Underperform

Reason

BofA analyst Tazeen Ahmad raised the firm's price target on Prothena (PRTA) to $8 from $4 and keeps an Underperform rating on the shares. Prothena no longer plans to disclose further data for its Alzheimer's drug PRX012, notes the firm, which removed value for the program from its model and is shifting focus on valuation to two Phase 3 assets under development by partners Novo (NVO) and Roche (RHHBY) - Coramitug for ATTR-cardiomyopathy and prasinezumab for early-stage Parkinson's disease. While both programs will have begun Phase 3 studies by year-end, which the firm views favorably for Prothena, the firm adds that each drug will need several years to reach the market and their competitive positioning in the case of Coramitug and clinical efficacy in the case of prasinezumab are "uncertain."

H.C. Wainwright

Buy

maintain

$20 -> $30

2025-11-07

Reason

H.C. Wainwright

Price Target

$20 -> $30

2025-11-07

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Prothena to $30 from $20 and keeps a Buy rating on the shares. The firm believes the market is overlooking the company's two partnered Phase 3 programs and a partnered Phase 2 asset with blockbuster potential.

Piper Sandler

NULL

Overweight

upgrade

$15 -> $36

2025-10-28

Reason

Piper Sandler

Price Target

$15 -> $36

2025-10-28

upgrade

NULL

Overweight

Reason

Piper Sandler raised the firm's price target on Prothena to $36 from $15 and keeps an Overweight rating on the shares. The firm recognizes the value of its partnered pipeline with lucrative potential across net sales royalties and milestone payments. Piper remains bullish on Prothena and believes that there is substantial upside opportunity heading into a catalyst-rich next 12 months-plus.

Citizens JMP

Jason Butler

Outperform

downgrade

$29 -> $11

2025-09-02

Reason

Citizens JMP

Jason Butler

Price Target

$29 -> $11

2025-09-02

downgrade

Outperform

Reason

Citizens JMP analyst Jason Butler lowered the firm's price target on Prothena to $11 from $29 and keeps an Outperform rating on the shares. Prothena last week reported results from cohort A of the Phase 1 PRX012 in Alzheimer's disease patients, with results demonstrating a favorable reduction in amyloid levels at the 200mg and 400mg doses, but this benefit was accompanied by elevated, uncompetitive ARIA incidence in PRX012-treated patients, the analyst tells investors in a research note. The ARIA AE profile likely makes PRX012 competitively unviable in early-stage AD patients, the firm says.

Piper Sandler

Overweight

downgrade

$81 -> $15

2025-08-28

Reason

Piper Sandler

Price Target

$81 -> $15

2025-08-28

downgrade

Overweight

Reason

Piper Sandler lowered the firm's price target on Prothena to $15 from $81 and keeps an Overweight rating on the shares. While the firm was disappointed to see PRX012's ASCENT program hit non-competitive rates of ARIA, Piper is not concerned about Prothena as the company has a high-value partnership pipeline ripe for future cash opportunities. Firstly, the firm thinks it is crucial not to minimize the ASCENT data as it effectively supports PRX012's mechanism and de-risks second generation, PRX012-TfR, with plans underway to seek potential partnership opportunities for both. Furthermore, Piper thinks there is a lot of value attached to Prothena's robust partnership pipeline. That said, the firm removed PRX012 in AD from its model as it is viewing potential partnership as an upside.

BofA

Tazeen Ahmad

Neutral -> Underperform

downgrade

$22 -> $4

2025-05-28

Reason

BofA

Tazeen Ahmad

Price Target

$22 -> $4

2025-05-28

downgrade

Neutral -> Underperform

Reason

BofA analyst Tazeen Ahmad downgraded Prothena to Underperform from Neutral with a price target of $4, down from $22.

Valuation Metrics

The current forward P/E ratio for Prothena Corporation PLC (PRTA.O) is 95.79, compared to its 5-year average forward P/E of -0.33. For a more detailed relative valuation and DCF analysis to assess Prothena Corporation PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.33

Current PE

95.79

Overvalued PE

30.92

Undervalued PE

-31.59

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.68

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

17.34

Undervalued EV/EBITDA

-28.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

81.98

Current PS

5.93

Overvalued PS

248.66

Undervalued PS

-84.70

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PRTA News & Events

Events Timeline

No data

News

5.0

12-12Newsfilter

Prothena Board Member Paula Cobb Resigns to Join Manifold Bio as COO

6.0

12-01Benzinga

Amazon Set to Surge by 31%? Check Out 10 Leading Analyst Predictions for Monday

9.0

11-12Benzinga

Novo Nordisk's Coramitug, a $100 Million Investment, Shows Potential in Lowering Heart Failure Biomarkers

People Also Watch

Frequently Asked Questions

What is Prothena Corporation PLC (PRTA) stock price today?

The current price of PRTA is 10.22 USD — it has decreased -1.35 % in the last trading day.

What is Prothena Corporation PLC (PRTA)'s business?

Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.

What is the price predicton of PRTA Stock?

What is Prothena Corporation PLC (PRTA)'s revenue for the last quarter?

Prothena Corporation PLC revenue for the last quarter amounts to 2.42M USD, increased 148.97 % YoY.

What is Prothena Corporation PLC (PRTA)'s earnings per share (EPS) for the last quarter?

Prothena Corporation PLC. EPS for the last quarter amounts to -0.68 USD, decreased -38.18 % YoY.

What changes have occurred in the market's expectations for Prothena Corporation PLC (PRTA)'s fundamentals?

How many employees does Prothena Corporation PLC (PRTA). have?

Prothena Corporation PLC (PRTA) has 163 emplpoyees as of December 15 2025.

What is Prothena Corporation PLC (PRTA) market cap?

Today PRTA has the market capitalization of 557.68M USD.